Prevalence

Plasma Fractionation Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 9, 2022
HYCON, Virus, Disease, CSL Limited, Shire (pharmaceutical company), Immune system, Antibody, Conditional sentence, Plasma, Glycoprotein, Takeda Pharmaceutical Company, Chronic condition, Hematology, Patient, Prevalence, Cancer, Immunodeficiency, Critical care, Bio Products Laboratory, Hospital, Takeda, Coagulopathy, Degenerative disease, LFB, Neurology, Diabetes, World Health Organization, Quality of life, Green Cross, COVID-19, Rheumatology, Inflammation, Growth, Octapharma, Death, Protease, B cell, Organization, Acquisition, Baxter International, Pharmaceutical industry, Lithium, Fine chemical, Blood product, Renewable energy, Takeda Oncology

The plasma fractionation market is expected to grow to $35.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.26%.

Key Points: 
  • The plasma fractionation market is expected to grow to $35.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.26%.
  • The plasma fractionation market consists of sales of plasma fractionation by entities (organizations, sole traders, and partnerships) that are used in the manufacture of essential pharmaceutical products that are used to treat immune deficiencies or bleeding disorders.Plasma fractionation refers to the process of separating the various components of blood plasma.
  • The regions covered in plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The plasma fractionation market research report is one of a series of new reports that provides plasma fractionation market statistics, including plasma fractionation industry global market size, regional shares, competitors with an plasma fractionation market share, detailed plasma fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the plasma fractionation industry.

Clinical Chemistry Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 9, 2022
Thermo Fisher Scientific, CVD, Infection, Randox Laboratories, Cancer, COVID-19, Risk, Serum, Siemens, Conditional sentence, Eastman Kodak Co. v. Image Technical Services, Inc., Research report, Stroke, Death, Growth, Urine test strip, Public health, Prevalence, Liver function tests, Disability, Cardiovascular disease, Diabetes, World Health Organization, Degenerative disease, Urine, USD, Acquisition, Water, Ortho Clinical Diagnostics, Myocardial infarction, Laboratory, Plasma, Chemistry, Chronic condition, Patient, Hospital, Abbott Laboratories, Clinical chemistry, WHO, Acute kidney injury, Organization, Fine chemical, Pharmaceutical industry

The global clinical chemistry market is expected to grow from $ 11.93 billion in 2021 to $ 12.76 billion in 2022 at a compound annual growth rate (CAGR) of 7%.

Key Points: 
  • The global clinical chemistry market is expected to grow from $ 11.93 billion in 2021 to $ 12.76 billion in 2022 at a compound annual growth rate (CAGR) of 7%.
  • The clinical chemistry market is expected to grow to $ 15.69 billion in 2026 at a CAGR of 5.3%.
  • The regions covered in the clinical chemistry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The clinical chemistry market research report is one of a series of new reports that provides clinical chemistry market statistics, including clinical chemistry industry global market size, regional shares, competitors with clinical chemistry market share, detailed clinical chemistry market segments, market trends and opportunities, and any further data you may need to thrive in the clinical chemistry industry.

Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class, Route of Administration, and Segment Forecast, 2022-2027

Retrieved on: 
Friday, December 9, 2022
Regenerative medicine, Gerber Products Company, Conditional sentence, Astellas Institute for Regenerative Medicine, Injection (medicine), Prevalence, Cancer, Plasma protein binding, US, Route of administration, Administration, Table, Corticosteroid, Pharmaceutical industry, Fine chemical, Pharma

The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.

Key Points: 
  • The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.
  • - Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
    - Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
  • - Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • - Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.

Topical Drug Delivery Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 9, 2022
United Nations, Therapy, Acquisition, Rosacea, Pfizer, Novartis, GlaxoSmithKline, Gel, Skin, Research report, Bausch Health, Powder, Bayer, Joint Medical Service (Germany), Patient, Prevalence, Information International, Inc., Hospital, Death, Coinces, Diabetes, World Health Organization, COVID-19, Growth, Benzoyl peroxide, First Nations in Ontario, Eos, Suppository, Organization, Pharmaceutical industry, Medical device

The topical drug delivery market is expected to grow to $186.51 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%.

Key Points: 
  • The topical drug delivery market is expected to grow to $186.51 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%.
  • The route of administration includes dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery.
  • Technological advancement is a key trend gaining popularity in the topical drug delivery market.Major companies operating in the topical drug delivery market are developing innovative products with advanced technologies to strengthen their position in the topical drug delivery market.
  • The topical drug delivery market research report is one of a series of new reports that provides topical drug delivery market statistics, including topical drug delivery industry global market size, regional shares, competitors with a topical drug delivery market share, detailed topical drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the topical drug delivery industry.

Extensive Stage Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032

Retrieved on: 
Thursday, December 8, 2022
Standard of care, Benchmarking, Durvalumab, Jazz Pharmaceuticals, Research report, Commercial, Lurbinectedin, Patient, Prevalence, Clinical, Carboplatin, Etoposide, Lung cancer, AstraZeneca, Disease, Platinum, Cisplatin, Survival, Squamous cell carcinoma, Region, Organization, Pharmaceutical industry, Uranium, Fine chemical, Vaccine

View original content:https://www.prnewswire.com/news-releases/extensive-stage-small-cell-lung...

Key Points: 
  • Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer.Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases.
  • The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study.
  • Since, the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased.F.
  • Competitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer.Moreover, a detailed competitive benchmarking of the players operating in the global extensive stage small cell lung cancer market has been included to help the reader understand how players stand against each other, presenting a clear market landscape.

Interpres Security Emerges from Stealth to Help Companies to Optimize Security Performance

Retrieved on: 
Thursday, December 8, 2022
MITRE, Ciso Morales, Ars Interpres, Netwitness, Security, Environment, Automation, Prevalence, Ping Identity, EMC, Intelligence, Investment, Face, Human, General partnership, Organization, Risk management

CHARLESTON, S.C., Dec. 8, 2022 /PRNewswire/ -- Interpres Security, a company dedicated to helping companies optimize their security performance with a comprehensive new approach to managing the defense surface, announced its emergence from stealth alongside $8.5M in seed financing led by Ten Eleven Ventures. The Interpres Security platform offers a customized, continuous, and threat-informed analysis of an organization's detection and mitigation capabilities and provides automated security engineering directives based on this evaluation, ultimately enabling a hardened security posture in the most efficient manner possible.

Key Points: 
  • CHARLESTON, S.C., Dec. 8, 2022 /PRNewswire/ -- Interpres Security, a company dedicated to helping companies optimize their security performance with a comprehensive new approach to managing the defense surface, announced its emergence from stealth alongside $8.5M in seed financing led by Ten Eleven Ventures.
  • After experiencing a systems breach firsthand at a classified security operations center, members of the Interpres Security founding team developed a new Threat Centric Methodology to validate the effectiveness of all of the security vendors in the environment.
  • "Until now, only large security engineering teams have even been able to attempt to analyze, validate, and optimize an organization's specific security toolset and processes.
  • Interpres Securitymakes security performance intelligible and provable for the enterprise with a comprehensive new approach to managing the defense surface.

ROSALIND FRANKLIN UNIVERSITY RESEARCHER AWARDED $1.2 MILLION FOR STUDIES ON DIABETIC FOOT ULCERS AND PREVENTION OF FALLS

Retrieved on: 
Wednesday, December 7, 2022
Rehabilitation, Leg, DFU, National Institute of Diabetes and Digestive and Kidney Diseases, Veteran, Department of Defense Serum Repository, Doctor of Philosophy, Rosalind Franklin University of Medicine and Science, Research, RFU, Kidney, Prevalence, Podiatry, Digestive, Diabetic foot ulcer, Diabetes, Human, Mental health, Quality of life, Multimedia, Orthotics, Amputation, Ulcer, Pharmaceutical industry, Medicine, Defense, RCW

NORTH CHICAGO, Ill., Dec. 7, 2022 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science scientists have been awarded $1.2 million in research grants from the National Institutes of Health and the Department of Defense to investigate barriers to foot health and mobility.

Key Points: 
  • NORTH CHICAGO, Ill., Dec. 7, 2022 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science scientists have been awarded $1.2 million in research grants from the National Institutes of Health and the Department of Defense to investigate barriers to foot health and mobility.
  • The National Institute of Diabetes and Digestive and Kidney Diseases awarded primary investigators Noah Rosenblatt , PhD, and Ryan Crews , PhD, a three-year, $848,596 grant to evaluate the impact of removable cast walker (RCW) designs on diabetic foot ulcer (DFU) healing.
  • But low adherence to the treatment predicts poor DFU healing, according to Dr. Rosenblatt.
  • "Dr. Rosenblatt's innovative research deserves this federal investment," said RFU's Executive Vice President of Research Ronald Kaplan, PhD.

New Trialjectory Data Shows Triple-Negative Breast Cancer Patients More Likely to Seek Clinical Trial Options Prior to Treatment for Advanced Disease

Retrieved on: 
Wednesday, December 7, 2022
Travel, Standard of care, TNBC, Invention, Poster, Triple-negative breast cancer, Patient, COVID-19 pandemic in the Democratic Republic of the Congo, Entrepreneurship, Prevalence, Cancer, Breast cancer, Disease, Motivation, TIME, AI, COVID-19, Clinical trial, Breast, Medical imaging, Pharmaceutical industry

NEW YORK, Dec. 7, 2022 /PRNewswire/ -- Trialjectory ("the Company''), an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials, announced today new data showing that triple-negative breast cancer (TNBC) patients are more likely to seek clinical trial options for their disease compared to other subtypes and, in advanced disease setting, sooner and prior to treatment compared to patients with non-triple-negative breast cancer. The findings were presented as part of a poster at this year's San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • The findings were presented as part of a poster at this year's San Antonio Breast Cancer Symposium (SABCS).
  • TNBC is an aggressive form of breast cancer associated with poor prognosis and accounts for 10 to 15 percent of all breast cancers.
  • Advanced TNBC patients initiated their clinical trial search earlier in their cancer journey, even before receiving chemotherapy, compared to non-TNBC patients (34 percent versus 22 percent).
  • Working directly with patients, healthcare providers and pharmaceutical companies, Trialjectory democratizes access to advanced cancer treatment and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials.

New Study Published on JAMA Network Finds Connection Between Mental Illness and Unmet Social Needs Among Seniors

Retrieved on: 
Wednesday, December 7, 2022
Doctor of Pharmacy, American Medical Association, Housing, Disease, Report, LOS, MPA, Conditional sentence, Poverty, Diagnosis, Hospital, Patient, Prevalence, TMS, Cancer, Cardiovascular disease, Addiction medicine, Diabetes, Nationwide, Happiness, MPH, Mental health, Eating disorder, Journal, Death, Food security, Multimedia, Mortality, Food, JAMA, Medicare, Psychiatry, Organization, Health insurance, Medicine, MD, Doctor of Philosophy, Discovery

LOS ANGELES, Dec. 7, 2022 /PRNewswire/ -- A  new study of 56,000 senior Americans published on JAMA Network, the online publication of the Journal of the American Medical Association, has found the prevalence and risks associated with health-related social needs, including food insecurity and inadequate housing, and mental illness.

Key Points: 
  • In this large cohort study of Medicare Advantage enrollees with and without mental illness, 38.6% had at least 1 mental illness diagnosis, 54.0% had a health-related social need (HRSN), and 25.3% had both mental illness and an HRSN in the past year.
  • The association of mental illness with the presence of HRSNs was most substantial among those with both serious and persistent mental illness.
  • Compared with the general population, those with mental illness have higher morbidity and mortality, and those with serious mental illness die a decade earlier.
  • Although many individuals in the U.S. have HRSNs, those with mental illness are at particularly high risk.

Immune Checkpoint Inhibitors Global Market Report 2022: Rising Prevalence of Cancer Boosts Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Immune system, Large-cell lung carcinoma, Immunotherapy, PD-L1, Gardasil, Protein, Patient, Prevalence, Rituximab, Cancer, US, Tisagenlecleucel, Research, Lung cancer, American Cancer Society, Breast cancer, PD-1, Market share, Lymphoma, Death, Nivolumab, Skin cancer, Marketing, Region, Neoplasm, Pharmaceutical industry, Vaccine, Uranium

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer.

Key Points: 
  • Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer.
  • Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells.
  • Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others.
  • The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market.